China sales are exploding too.
See you there.
Big audience will listen.
You need to download the complete brochure on the conference web page. He is listed on page 23 or 25. Please do better DD.
Feb 8th news.
Feb 8th news !
See Feb 8th news!
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications, including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia, and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.
See company web page for all news releases. Human trials just extended drug for 2 years due to amazing results. Patients and caregivers asked for the addition extention from 26 weeks to 52 weeks now 2 years!!
Time slots have been updated for the May symposium.
Dr. Missling will be speaking from 15.40-16.10, a hefty 30 minutes. That should be more than enough time to go over lots and lots of data!